BSX beats Q2 estimates, raises full-year outlook as Cardiovascular sales surge and global revenues climb 22.8%.
Boston Scientific Corporation (NYSE:BSX ) Q2 2025 Earnings Conference Call July 23, 2025 8:00 AM ET Company Participants Jonathan R. Monson - Executive VP & CFO Kenneth M.
Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
21 Oct 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
23 Jul 2025 Date | | 0.73 Cons. EPS | - EPS |
22 Jul 2025 Date | | - Cons. EPS | - EPS |
22 Apr 2025 Date | | - Cons. EPS | - EPS |
29 Jan 2025 Date | | - Cons. EPS | - EPS |
21 Oct 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
23 Jul 2025 Date | | 0.73 Cons. EPS | - EPS |
22 Jul 2025 Date | | - Cons. EPS | - EPS |
22 Apr 2025 Date | | - Cons. EPS | - EPS |
29 Jan 2025 Date | | - Cons. EPS | - EPS |
Medical - Devices Industry | Healthcare Sector | Michael F. Mahoney CEO | XBER Exchange | US1011371077 ISIN |
US Country | 53,000 Employees | - Last Dividend | 6 Nov 2003 Last Split | 18 May 1992 IPO Date |
Boston Scientific Corporation is a global developer, manufacturer, and marketer of medical devices used in a variety of interventional medical specialties. Having begun its operations in 1979, the company has grown to serve a diverse range of medical needs through its two primary segments: MedSurg and Cardiovascular. With its headquarters in Marlborough, Massachusetts, Boston Scientific is committed to improving patient health by providing cutting-edge solutions that address complex medical conditions and enhance the quality of life for patients worldwide.